Effect of erythropoietin (EPO) on cognitive function and frontal lobe activity in patients with bipolar disorder and recurrent depression in remission and healthy first degree relatives with cognitive impairments (PRETEC-EPO) Effekt af erythropoietin (EPO) på kognitiv funktion og frontallapsaktivitet hos patienter med bipolar lidelse eller tilbagevendende depression i remission og raske fØrstegradsslægtninge med kognitive vanskeligheder (PRETEC-EPO)

Trial Profile

Effect of erythropoietin (EPO) on cognitive function and frontal lobe activity in patients with bipolar disorder and recurrent depression in remission and healthy first degree relatives with cognitive impairments (PRETEC-EPO) Effekt af erythropoietin (EPO) på kognitiv funktion og frontallapsaktivitet hos patienter med bipolar lidelse eller tilbagevendende depression i remission og raske fØrstegradsslægtninge med kognitive vanskeligheder (PRETEC-EPO)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Epoetin alfa (Primary)
  • Indications Bipolar disorders; Cognition disorders; Depression
  • Focus Therapeutic Use
  • Acronyms PRETEC-EPO
  • Most Recent Events

    • 25 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top